Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Randomized, Double-blind, Placebo-controlled Phase III Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975
A phase I/II trial of Cabozantinib in combination with Durvalumab MEDI4736 with or without Tremelimumab in patients with advanced gastroesophageal cancer and other gastrointestinal GI malignancies CAMILLA
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ? 1 Advanced Gastric and Esophageal Adenocarcinoma PARAMUNE
Study Type: Treatment
Phase: II/III
NCTID: NCT06203600
Principal Investigator:
Gary Doolittle
A Phase II, Open-Label, Single-Arm Trial of [Fam]-Trastuzumab Deruxtecan DS-8201a in HER2-Positive, Unresectable and/or Metastatic Gastric or Gastro-Esophageal Junction GEJ Adenocarcinoma Subjects Who Have Progressed On or After A Trastuzumab-Containing Regimen
A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction GEJ Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumor Have Claudin CLDN 18.2 Expression
Study Type: Treatment
Phase: I
NCTID: NCT05365581
Principal Investigator:
Anup Kasi
A Multicenter, Randomized, Open-Label, Phase III Trial of Trastuzumab Deruxtecan Enhertu� Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction GEJ Cancer Destiny-Gastric05
Study Type: Treatment
Phase: III
NCTID: NCT06731478
Principal Investigator:
Weijing Sun